Tirzepatide is the drug most people mean when they talk about Mounjaro or Zepbound, and telehealth companies sell a cheaper, vial-based version of it online. So what is compounded tirzepatide? It’s tirzepatide that a compounding pharmacy mixes to order. It has the same dual GIP/GLP-1 receptor agonist that powers the Eli Lilly brands, but prepared […]
By Astra Editorial Team
Published:
Updated:
Tirzepatide is the drug most people mean when they talk about Mounjaro or Zepbound, and telehealth companies sell a cheaper, vial-based version of it online. So what is compounded tirzepatide?
It’s tirzepatide that a compounding pharmacy mixes to order. It has the same dual GIP/GLP-1 receptor agonist that powers the Eli Lilly brands, but prepared by a pharmacy instead of made in Lilly’s own plants. Compounded tirzepatide holds no FDA approval and isn’t generic.
Below: what compounded tirzepatide actually is, how it measures up against Zepbound, Mounjaro, and semaglutide, whether it works, the safety issues regulators and Lilly have raised, what it runs, and how to source it without getting burned.
Quick answer: Compounded tirzepatide is essentially tirzepatide made to order by a licensed compounding pharmacy. It has the same active ingredient inside Mounjaro and Zepbound, minus the FDA approval and independent testing.
What makes tirzepatide distinctive is its mechanism: it activates two gut-hormone receptors, GIP and GLP-1, where most weight-loss injectables act on GLP-1 alone. Lilly markets it as Mounjaro for type 2 diabetes and as Zepbound for weight management (approved November 2023, and later for obstructive sleep apnea).
Compounded tirzepatide puts that molecule into formats the brands don’t sell: multi-dose vials you fill a syringe from, oral drops or tablets, and microdoses.
Read more on compounded GLP-1s and how they work here.
Quick answer: The drug inside is identical. Lilly makes the brands to a fixed, FDA-reviewed spec; compounded tirzepatide is not FDA-approved and varies by pharmacy. It is not a generic.
| Compounded tirzepatide | Mounjaro / Zepbound | |
|---|---|---|
| FDA approved? | No | Yes |
| Reviewed for safety/efficacy? | No | Yes |
| Made by | Compounding pharmacies (503A) or outsourcing facilities (503B) | Eli Lilly’s FDA-registered plants |
| Active ingredient source | Varies; Lilly doesn’t supply bulk tirzepatide | Lilly |
| Delivery | Usually vial + syringe | Prefilled pen (or Lilly vials) |
| Dosing | Variable, including non-standard doses | Fixed, pre-measured, clinically studied |
For a one-to-one brand comparison, see compounded tirzepatide vs. Zepbound.
Same active ingredient as Zepbound and Mounjaro. All-in, no membership, flat pricing at every dose. Licensed clinician reviews every prescription.
See if you qualify →Quick answer: Tirzepatide hits two receptors (GIP and GLP-1) while semaglutide hits one (GLP-1). Head-to-head, tirzepatide drove more weight loss at around 21.6% versus 15.4% for semaglutide.
Both are once-weekly peptide injections, but tirzepatide’s second mechanism tends to translate into bigger results. In Lilly’s SURMOUNT-5 trial, tirzepatide (Zepbound) outperformed semaglutide (Wegovy), with 71.2% of tirzepatide users shedding at least 15% of their body weight against 46% on semaglutide.
Which one suits you is a clinical call. Our semaglutide vs. tirzepatide piece and the compounded semaglutide guide go deeper.
Quick answer: Compounded tirzepatide became bigger during the 2022-2024 Mounjaro and Zepbound shortage. Now that the shortage is closed, only patient-specific compounding backed by a documented medical reason is still allowed.
While supply was short (Mounjaro landed on the shortage list in December 2022), the law let both 503A pharmacies, which fill one prescription at a time, and FDA-registered 503B outsourcing facilities, which produce larger batches, reproduce the drug.
That window closed when the FDA declared the shortage over in October 2024, revisited the call after a legal challenge, and reaffirmed it in December 2024; the wind-down deadlines for pharmacies have passed.
The exception still on the table is genuinely patient-specific: a reaction to an inactive ingredient in the branded product or a dose or form Lilly doesn’t manufacture. Simply wanting a lower price doesn’t count, and the FDA has sent warning letters to companies still marketing unapproved versions.
In trials, tirzepatide’s top dose led to ~21% body weight loss, more than semaglutide managed head-to-head. Astra’s compounded version starts at $118/month on a 12-month plan, prescribed by a licensed clinician and filled by a US-licensed 503A pharmacy.
Start your health profile →Quick answer: The active ingredient is one of the most effective weight-loss drugs on the market with roughly 20% average loss in trials. A compounded batch uses the same molecule, so it can deliver, but its strength depends on the pharmacy.
Tirzepatide’s evidence base is deep. Across the SURMOUNT program, it produced 16% to 22.5% average weight loss in adults with obesity, and SURMOUNT-4 showed people who kept taking it reaching about 25% total loss. It works for sleep apnea, too: SURMOUNT-OSA recorded large drops in apnea events.
That said, every one of those figures comes from FDA-approved tirzepatide at a tested dose. There are no trials for compounded tirzepatide specifically since it isn’t standardized. A published self-experiment using compounded tirzepatide managed a small short-term loss.
Quick answer: Side effects match brand-name tirzepatide, but compounding stacks on extra hazards that regulators and Lilly have specifically named, such as shaky ingredient sourcing, counterfeits, self-dosing mistakes, and batch variation. The pharmacy is the deciding factor.
Worth knowing before you consider it:
The everyday side effects track the brands’ — nausea, diarrhea, vomiting, constipation — with rarer serious risks such as pancreatitis and gallbladder trouble.
Quick answer: Go through a provider that writes an actual prescription after a clinician evaluation and names the accredited, sterile-licensed pharmacy filling it. Anyone offering “research-grade” or no-prescription tirzepatide is a hard no.
If your prescriber decides a compounded version fits, the pharmacy behind it is the thing to scrutinize:
A licensed clinician at Wasef Health, PC reviews your health profile and tells you honestly which fits your case. No pressure, no upsell. Astra offers all four options, so the recommendation reflects your situation, not the platform’s inventory.
Talk to a clinician →Fewer providers offer compounded tirzepatide legitimately than the ad volume suggests, and headline prices routinely omit membership dues or dose ceilings. Rates below are current as of August 2026:
| Provider | Compounded tirzepatide | Rx + licensed prescriber | Effective monthly (best plan) | Watch for |
|---|---|---|---|---|
| Astra | Yes (plus semaglutide, microdose) | Yes | from $118/mo | All-inclusive; no membership; flat at every dose |
| TrimRx | Yes | Yes | $283-$399/mo | No membership fee |
| Mochi Health | Yes | Yes | $90-$199/mo + membership | Membership required |
| Henry Meds | Yes | Yes | $1,047 (compounded oral tirzepatide, 3-mo supply) | Daily dissolving tablets |
Brand-name pens and manufacturer self-pay plans are all laid out on the GLP-1 Telehealth Price Index.
Quick answer: Astra’s compounded tirzepatide is $250 per month when paid monthly, and drops to $118 per month on the annual plan ($1,416 up front). That’s the one all-in price, the same at every dose, with no membership on top.
The longer the commitment, the lower the monthly rate:
| Astra plan (compounded tirzepatide) | Per month |
|---|---|
| 12-month plan (best value) | $118/mo ($1,416 total) |
| 6-month plan | $158/mo |
| 3-month plan | $166/mo |
| Monthly | $250/mo |
Each plan bundles the provider consultation, unlimited doctor messaging, shipping, and supplies, with no separate membership charge. Leaning toward semaglutide instead? Compounded semaglutide starts at $68/mo on the annual plan.
Astra’s compounded tirzepatide starts at $118/month on the 12-month plan. All-in, flat pricing, US-licensed 503A pharmacy, clinician-reviewed.
Start your health profile Takes about 5 minutes.Tirzepatide is the drug. Mounjaro and Zepbound are FDA-approved and built by Eli Lilly. A compounded version is the same drug prepared by a pharmacy, without FDA approval or independent testing.
Dose for dose, it’s the identical molecule, so it can behave the same way. But a compounded batch isn’t standardized or verified the way Mounjaro is, so its real strength comes down to the pharmacy that made it.
For weight loss, tirzepatide usually edges out semaglutide (the ingredient in Ozempic and Wegovy). The SURMOUNT-5 head-to-head trial had tirzepatide producing the larger drop in body weight.
Yes, for most people who tolerate it and titrate up to an effective dose, tirzepatide drives substantial loss alongside diet and activity. A compounded version carries the same active ingredient, so results are realistic, if not guaranteed to match the trial numbers.
Expect something in the range of 5% to 10% of body weight over the first few months; whether that adds up to 20 lbs depends on where you start, and none of it is promised. Gradual loss as the dose climbs is the normal pattern.
Appetite usually shifts within a few weeks, but the scale moves over months. A too-low dose, early titration, or a weak batch can all stall things. Check with your prescriber before writing it off.
Go easy on alcohol, don’t stack it with other GLP-1 or GIP drugs, and give your prescriber your full medication list. Tirzepatide can blunt the effect of oral birth control, so a backup method may be recommended. None of this replaces your provider’s guidance.
The GI effects, especially nausea, tend to peak in the opening weeks and just after each dose bump, then settle.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed physician regarding any medical condition or treatment.